New combo attack: surgery and drugs take on tough liver cancer

NCT ID NCT04649489

Ongoing Disease control Sponsor: Jia Fan Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether liver surgery followed by two drugs (atezolizumab and bevacizumab) can help people with liver cancer that has spread into veins. The study includes 501 participants who have not had prior treatment. The goal is to see if this approach delays cancer progression and improves survival compared to drug treatment alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs)
What this could lead to: If successful, this could show that combining surgery with these drugs improves survival for people with advanced liver cancer and vein clots.
What could go wrong: This is an early-stage trial with no results yet. The combination may not work better than current treatments, and surgery carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma thrombophilia due to thrombin defect Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENOUS THROMBOSIS

Contacts and locations

Locations

Anhui Provincial Hospital

Hefei, China
Beijing Cancer Hospital

Beijing, China
Cancer Hospital Chinese Academy of Medical Science

Beijing, China
Fujian Provincial Hospital

Fuzhou, China
Guangxi Medical University Cancer Hospital

Nanning, China
Henan Province People Hospital

Zhengzhou, China
Jiangsu Provine People Hospital

Nanjing, China
Mengchao Hepatobiliary Hospital of Fujian Medical University

Fuzhou, China
Peking Union Medical College Hospital

Beijing, China
Peking Univerty People's Hospital

Beijing, China
Shanghai Jiao Tong University Ruijin Hospital

Shanghai, China
Sun Yat-sen University Cancer Center

Guangzhou, China
The First Affiliated Hospital Of Guangxi Medical University

Nanning, China
The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China
The First Hospital of Lanzhou University

Lanzhou, China
The Second Affiliated Hospital Kunming Medical University

Kunming, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, China
Tongji Hospital of Tongji Medical College of HUST

Wuhan, China
West China Hospital of Sichuan University

Chengdu, China
Xiangya Hospital of Central South University

Changsha, China
Zhongshan hospital, Fudan University

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.